Background: Cytophagic histiocytic panniculitis (CHP) is a rare autoimmune disease that can mimic both lupus panniculitis (LP) and subcutaneous panniculitis-like T cell lymphoma (SPTL). Diagnosis is challenging due to overlapping histologic characteristics of these entities. It has historically been considered a pre-malignant lesion, with few case reports detailing CHP as its own entity.Case Presentation: We describe two cases of panniculitis with histologic features similar to both LP and SPTL. Neither patient had clinical or laboratory features convincing of systemic lupus erythematosus (SLE), which made a diagnosis of LP unlikely; T-cell receptor (TCR) gene rearrangement studies demonstrated a polyclonal lymphocytic infiltrate, suggestive of a non-malignant process. Both patients were diagnosed with CHP and responded well to tacrolimus therapy. Conclusions: CHP is a distinct clinical entity, and the panniculitis need not fall under a diagnosis of LP or SPTL. TCR gene rearrangement studies are an essential part of the evaluation to demonstrate polyclonality of the benign lymphocytic infiltrate. T-cell directed therapy represents a rational approach to treatment and yielded success in these two patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.